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E-mail address: l.wang@hsc.utah.edu (L. Wang).Mdm2 is a crucial negative regulator of the tumor suppressor function of p53. However, little is
known about Mdm2 protein stability regulation by other tumor suppressors. Nuclear receptor small
heterodimer partner (SHP, NROB2) functions as a tumor suppressor in liver cancer. We show here a
surprising ﬁnding of a feedback regulatory loop between SHP and Mdm2. SHP stabilizes Mdm2 pro-
tein by abrogating Mdm2 self-ubiquitination, andMdm2 in turn attenuates SHP protein levels under
p53-deﬁcient conditions. Such cross-regulation critically depends on the physical interaction of SHP
with Mdm2 through the SHP K170 residue. The Mdm2–SHP interplay represents a novel component
of Mdm2 signaling that is likely to dictate Mdm2 activity and function.
Structured summary of protein interactions::
MDM2 physically interacts with SHP by anti tag coimmunoprecipitation (View Interaction: 1, 2)
SHP physically interacts with MDM2 by anti bait coimmunoprecipitation (View Interaction: 1, 2)
MDM2 physically interacts with p53 by anti tag coimmunoprecipitation (View Interaction: 1, 2)
SHP physically interacts with p53 by anti bait coimmunoprecipitation (View Interaction: 1, 2)
p53 physically interacts with SHP by anti tag coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Small heterodimer partner (SHP, NROB2), a unique member of
the nuclear receptor superfamily, is a pleiotropic transcriptional
regulator of genes involved in various metabolic diseases [1–17].
Our recent studies also identiﬁed SHP as a critical regulator of
microRNA expression and function [18–25]. Interestingly, we ob-
served spontaneous hepatocellular carcinoma (HCC) formation in
SHP/ mice due to hepatocyte hyperproliferation [26] and de-
creased apoptosis [27]. SHP expression was also diminished in hu-
man HCC by epigenetic silencing of the SHP promoter [28],
suggesting that SHP is a good prognostic factor in HCC [29]. Impor-
tantly, SHP functions as a transcriptional repressor of DNA methyl-
transferase Dnmt1 expression via ERRc [30] and zinc/MTF-1
mediated regulation [31]. Despite these important ﬁndings, in par-
ticular the novel tumor suppressor function of SHP in liver cancer,
it is poorly understood how SHP regulates carcinogenesis through
cross-interaction with other tumor suppressors or oncogenes.
Mdm2 is a well characterized negative regulator of the tumor
suppressor p53 [32]. The direct binding of Mdm2 to p53 inhibits
the transcriptional activation function of p53 [33]. Mdm2 targetschemical Societies. Published by Ep53 for proteasomal degradation through Mdm2 E3 ubiquitin li-
gase activity [34]. Phosphorylation of Mdm2 inhibits its E3 ligase
activity and prevents the ability of Mdm2 to repress p53 [35,36].
Mdm2 also suppresses p53 translation by interacting directly with
p53 mRNA [37], or by targeting ribosomal protein RPL26 for degra-
dation [38]. Mdm2 is overexpressed in a variety of human tumors,
consistent with a role as an oncogene [39]. However, growing evi-
dence suggests Mdm2 as a tumor suppressor under speciﬁc phys-
iological conditions. Loss of Mdm2 in a p53 mutant mouse model
enhanced tumor formation [40]. Mdm2 facilitates nuclear export
of p53 [41], thereby activating the p53-mediated mitochondrial
apoptotic pathway [42] and contributing to the tumor suppressor
activity of p53 [43]. These observations suggest that Mdm2 may
play as a double-edged sword in tumorigenesis.
Currently, little is known about Mdm2 protein stability regula-
tion by other tumor suppressors and how this may contribute to its
tumor suppressor function under certain cellular contexts. As a
potential additional layer of regulation of protein stability, the
present study explored the crosstalk between SHP and Mdm2.
Demonstration of a feedback loop between SHP and Mdm2 reveals
a ﬁne tuned interplay of SHP and Mdm2 proteins. The ﬁndings pro-
vide the ﬁrst evidence that Mdm2 protein stability is enhanced by
a nuclear transcriptional repressor.lsevier B.V. All rights reserved.
Fig. 1. SHP drastically increases endogenous Mdm2 protein expression. (A)
Western blots to determine both endogenously (Endo-Mdm2) and exogenously
(HA-Mdm2) expressed Mdm2 protein in different cell lines using anti-Mdm2
antibodies. HepG2 cells showed the highest levels of Mdm2 protein than other cell
lines. (B and C) Western blots to determine the effect of overexpession (B) or
knockdown (C) SHP on endogenous Mdm2 protein expression in HepG2 cells. Ade,
adenoviruses. Mdm2, SHP (both Flag-SHP and Endo-SHP) and p53 proteins were
detected using anti-Mdm2, anti-SHP and anti-p53 antibodies, respectively.
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2.1. Plasmids and reagents
Plasmids were obtained from Drs. Xiongbin Lu (HA-Mdm2)
[44], Takeshi Imamura (HA-Ub) [45], Yang Shi (Myc-Ub) [46], and
Moshe Oren (Mdm2DR, Mdm2DA) [38]. Other plasmids were from
our laboratory [16] or purchased from Addgene. Antibodies against
human MDM2, HA-tag, and b-actin were purchased from Sigma.
M2 antibody, anti-FLAG M2 Magnetic Beads and anti-HA agarose
were purchased from Sigma. Mouse monoclonal antibody against
Myc-tag was purchased from Cell Signaling. MagneGST™ pull-
down kit was obtained from Promega.
2.2. Cell culture and transfection
HepG2, Hela, HEK293T, and HCT116 cells were cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) with 10% fetal bovine
serum. Transfection was performed by Lipofectamine 2000 accord-
ing to the manufacturer’s instructions.
2.3. Co-immunoprecipitation
HEK293T cells were transfected with the indicated plasmids
using Lipofectamine 2000 (Invitrogen), lysed in 500 ll lysis buffer
and immunoprecipitated with anti-FLAG M2 Magnetic Beads (Sig-
ma) for 4 h at 4 C. The beads were washed four times with the ly-
sis buffer. The bound proteins were separated by SDS–PAGE,
followed byWestern blotting with the indicated antibodies accord-
ing to the standard procedures.
2.4. Ubiquitination assay
As described previously, FLAG-tagged SHP or HA-tagged Mdm2
was transfected with HA-ubi or myc-ubi into HEK293T cells for
24 h, then treated with 5 mM MG132 (Cayman) for additional
6 h. Cells were harvested and lysed in 500 ll of lysis buffer and
immunoprecipitated with anti-FLAG M2 magnetic beads (Sigma)
for 4 h at 4 C. The beads were washed three times with the lysis
buffer and analyzed with anti-HA, anti-FLAG or anti-myc antibody
by Western blots.
2.5. Statistical analysis
Data are expressed as mean ± S.E.M. Statistical analyses were
carried out using Student’s unpaired t test; P < 0.01 was considered
statistically signiﬁcant.
3. Results
3.1. SHP drastically increases endogenous Mdm2 protein expression
To identify a cell model that has abundant endogenous Mdm2
and SHP expression, we examined several cell lines and found
HepG2 cells express high levels of Mdm2 (Fig. 1A). HepG2 cells also
express abundant SHP, as reported in our earlier studies [28], thus
were used for examining changes of endogenous Mdm2 by SHP
overexpression and knockdown.
Introducing a wild-type (WT) SHP expression plasmid in HepG2
cells markedly increased endogenous Mdm2 protein, as examined
by a speciﬁc Mdm2 antibody (Fig. 1B). Due to the short exposure
time, Mdm2 protein was not detected in SHP non-transfected cells.
In contrast, knockdown of SHP using SHP siRNA adeniviruses re-
duced Mdm2 protein, which was accompanied by an induction ofp53 protein (Fig. 1C). The results suggest that SHP positively regu-
lates endogenous Mdm2 protein expression.
3.2. SHP markedly stabilizes exogenously expressed Mdm2 protein
We next tested whether SHP could affect exogenously ex-
pressed Mdm2 protein levels. Hela cells were used because of sev-
eral advantages, including expressing low endogenous Mdm2,
having higher transfection efﬁciency, and having been successfully
expressed with a HA-tagged Mdm2 protein (Fig. 1A).
The SHPWT, as well as several naturally occurring human SHP
mutations SHPK170N, SHPR38H, and SHPG171A [16], were exam-
ined. Overexpression of SHPWT, SHPK170N, SHPR38H, and
SHPG171A increased the HA-Mdm2 protein in a dose-dependent
fashion (Fig. 2A and B). For a better comparison of the efﬁcacy of
individual SHP mutant, we conducted Western blots in a single
gel. Interestingly, SHPK170N had the lowest expression due to its
increased ubiquitination [16], however, it showed the strongest
ability to increase Mdm2 protein, whereas SHPR38H and
SHPG171A exhibited weaker effects than SHPWT (Fig. 2C).
To address the question that the induction of Mdm2 protein by
SHP is not due to increased Mdm2 synthesis, we treated the cells
with protein synthesis inhibitor cycloheximide (CHX). The half-life
of Mdm2 protein was signiﬁcantly increased in SHP co-expressed
cells compared with cells without SHP expression (Fig. 2D), the la-
ter showed barely detectable Mdm2 protein because of short expo-
sure time.
Overall, the results in Fig. 2 suggest that SHP stabilizes exoge-
nously expressed Mdm2 protein, likely through slowing down
Mdm2 degradation.
3.3. SHP and Mdm2 interaction via SHPK170 is important to protect
Mdm2 from self-ubiquitination
Because Mdm2 undergoes self-ubiquitination and degradation
[32,36], it is postulated that SHP may affect Mdm2 protein stability
by modulating its ubiquitination. In vitro ubiquitination assays
were performed in 293T cells that produce suitable amounts of
ectopically expressed proteins for Co-IP experiments.
In the presence of SHP co-expression, the ubiquitinated Mdm2
was markedly reduced (Fig. 3A). Because SHPK170N exhibited
the highest potency to increase Mdm2 protein (Fig. 2C), we mu-
tated K170 to a positively charged Arg (K170R) to further examine
Fig. 2. SHP markedly stabilizes exogenously expressed Mdm2 protein. (A–C)
Western blots to determine the effects of SHPWT (wild type), SHPK170N, SHPR38H,
or SHPG171A on exogenously expressed HA-Mdm2 protein expression in Hela cells.
Mdm2 and SHP proteins were detected using anti-HA and anti-Flag antibodies,
respectively. (D) Western blots to determine the effect of SHP on Mdm2 protein
half-life in the presence of protein synthesis inhibitor cycloheximide (CHX).
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SHPK170R failed to inhibit Mdm2 ubiquitination (Fig. 3B), which
correlated with its lack of effect to increase Mdm2 protein expres-
sion (Fig. 3C).Fig. 3. Overexpression of SHP protects Mdm2 from self-ubiquitination. (A and B) In vit
Mdm2 protein ubiquitination (indicated by a solid line) in 293T cells. (C) Western blots to
proteins were detected using anti-HA and anti-Flag antibodies, respectively. (D) Immuno
and SHPK170R proteins with the Mdm2 protein. Anti-HA antibody was used to IP Mdm2
blots, respectively.Co-IP and Western blots revealed a weak binding between
SHPWT and Mdm2, which was markedly enhanced by the K170N
mutation, but abolished by the K170R mutation (Fig. 3D). The
results suggest that the interaction of SHP and Mdm2 is important
for SHP regulation of Mdm2 self-ubiquitination and that the SHP
K170 residue plays a critical role for SHP interaction with Mdm2.
3.4. The in vivo interaction of SHP with Mdm2 is independent of p53
Next, HepG2 cells were used to determine whether SHP and
Mdm2 proteins were directly associated with each other in vivo
in cells using anti-Mdm2 and anti-SHP antibodies. The endogenous
SHP protein was immunoprecipitated with Mdm2 protein in
HepG2 cells (Fig. 4A). Interestingly, we also found SHP was immu-
noprecipitated with the p53 protein. To further deﬁne the nature of
the protein–protein interaction between SHP and Mdm2, we used
p53 deﬁcient cells. SHP exhibited a similar ability to interact with
Mdm2 in HCT116p53/ cells as compared to the HCT116p53+/+
cells (Fig. 4B). Our data demonstrate that the SHP/Mdm2 interac-
tion is independent of the presence of p53.
3.5. p53-deﬁciency augments SHP degradation by Mdm2
Because Mdm2 has intrinsic E3 ligase activity and regulates the
turnover of numerous signaling proteins, we characterized the
cross-regulation between Mdm2 and SHP in HCT116p53+/+ and
HCT116p53/ cells using anti-Mdm2 and anti-SHP antibodies.
Mdm2DR (C-terminal RING domain deletion) and Mdm2DA (acidic
domain deletion) [38] were used for comparison. Mdm2DR lacks
intrinsic E3 ligase activity and self-ubiquitination, and thus was ex-
pressed at much higher levels than Mdm2DA and Mdm2 in
HCT116p53/ cells (Fig. 5A, row 1, lane 2 vs. 1&3) and
HCT116p53+/+ cells (row 1, lane 20 vs. 10&30). Co-expression of
SHPWT with Mdm2 signiﬁcantly elevated Mdm2 to similar levels
as Mdm2DR in both HCT116p53/ (row 1, lane 5 vs. 6) and
HCT116p53+/+ cells (row 1, lane 50 vs. 60). The observation conﬁrms
that SHP-mediated Mdm2 protein stability is associated with
Mdm2 ubiquitinaton and is also independent of p53.
To our surprise, SHP levels were markedly downregulated by
Mdm2 co-expression in p53-deﬁcient HCT116p53/ cells (row 2,ro ubiquitination assays to determine the effect of SHPWT (A) or SHPK170R (B) on
determine the effect of SHP170R on HA-Mdm2 protein expression. Mdm2 and SHP
precipitation and Western blots to determine the association of SHPWT, SHPK170N
, and anti-Flag or anti-HA antibodies were used to detect SHP or Mdm2 in Western
Fig. 4. The in vivo interaction of SHP with Mdm2 is independent of p53. (A)
Immunoprecipitation andWestern blots to determine the in vivo association of SHP
with Mdm2 or p53 in HepG2 cells. Anti-SHP antibody was used to IP SHP, and anti-
Mdm2, anti-SHP or anti-p53 antibodies were used to detect Mdm2, SHP or p53 in
Western blots, respectively. (B) Immunoprecipitation and Western blots to deter-
mine the in vivo association of SHP with Mdm2 or p53 in HCT116p53+/+ and
HCT116p53/ cells. Anti-SHP antibody was used to IP SHP, and anti-Mdm2, anti-
p53 or anti-SHP antibodies were used to detect Mdm2, p53 or SHP in Western blots,
respectively.
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lane 50 vs. 40). Mdm2DR and Mdm2DA affected SHP turnover to the
same extent as its wild-type counterpart in both cells (row 2, lanes
6&7 vs. 5, lane 60&70 vs. 50).
To conﬁrm SHP downregulation by Mdm2, Hela cells, which
have no functional p53, were used as an additional cell model.
Overexpressing Mdm2 reduced SHP protein levels by about 40–
50% (Fig. 5B). In addition, SHP protein showed a short half-life
(Fig. 5C), consistent with early observations [16,47]. The half-life
of SHP protein was shortened from 30 min to 15 min upon
Mdm2 overexpression (Fig. 5C). Overall, the results suggest that
in the absence of p53, Mdm2 is able to cause rapid SHP
degradation.Fig. 5. The reduction of SHP protein by Mdm2 is enhanced by p53-deﬁciency. (A) West
expression in HCT116p53/ and HCT116p53+/+ cells. The Mdm2, SHP and p53 proteins
Western blots to determine the effect of Mdm2 on exogenously expressed SHP protein ex
anti-HA antibodies, respectively. (C) Western blots to determine the effect of Mdm2 on
(CHX).3.6. Mdm2 and p53 bind preferentially to each other rather than to
SHP
Thus far, we observed that SHP interacted with both Mdm2 and
p53. Mdm2 is known to interact strongly with p53. The next ques-
tion is whether Mdm2 and p53 binding could be disrupted by SHP.
293T cells were used for Co-IP experiments. The amount of immu-
noprecipitated Mdm2 associated with SHP was attenuated with
increasing amounts of p53 expression, likely due to the enhanced
Mdm2 and p53 interaction (Fig. 6A). In addition, the association
of SHP with p53 was also decreased by co-expression of Mdm2
due to increased Mdm2 binding to p53 (Fig. 6B). The data suggest
that Mdm2 competes for binding between SHP and p53, and p53
competes for binding between SHP and Mdm2. Thus, the binding
between SHP and Mdm2 or SHP and p53 is weaker than the bind-
ing between Mdm2 and p53.
4. Discussion
In this study, we show that SHP markedly increases Mdm2 pro-
tein stability by preventing Mdm2 self-ubiquitination. Mdm2 also
causes rapid SHP degradation under p53-deﬁcient conditions, thus
creating an autoregulatory loop with SHP. Our study reveals a ﬁne
tuned interplay between SHP and Mdm2, which provides new in-
sight into the mechanisms of Mdm2 activation mediated by a nu-
clear transcriptional repressor.
The recent discovery of certain natural occurring SHP variants
provided key insights into the structural basis of the SHP–Mdm2
interaction. Despite its lower stability SHPK170N shows the high-
est ability to induce Mdm2 protein, whereas the more stable
SHPK170R is unable to induce Mdm2 protein or decrease its degra-
dation. This likely reﬂects the enhanced binding of Mdm2 to
SHPK170N and its decreased binding to SHPK170R. Therefore,
K170 appears to be a critical lysine residue through which SHP ex-
erts its activity to regulate Mdm2 protein stability. On the other
hand, the Mdm2 and SHP interaction is independent of p53, andern blots to determine the effects of Mdm2, Mdm2DR or Mdm2DA on SHP protein
were detected using anti-Mdm2, anti-SHP or anti-p53 antibodies, respectively. (B)
pression in Hela cells. The SHP and Mdm2 proteins were detected using anti-Flag or
SHP protein half-life in the presence of protein synthesis inhibitor cycloheximide
Fig. 6. Mdm2 and p53 bind preferentially to each other rather than to SHP. (A)
Immunoprecipitation and Western blots to determine the effect of p53 on SHP–
Mdm2 interaction. Anti-HA antibody was used to IP Mdm2, and anti-Flag, anti-Myc
or anti-HA antibodies were used to detect SHP, p53 or Mdm2 proteins in Western
blots, respectively. (B) Immunoprecipitation and Western blots to determine the
effect of Mdm2 on SHP–p53 interaction. Anti-Myc antibody was used to IP p53, and
anti-Flag, anti-HA or anti-Myc antibodies were used to detect SHP, Mdm2 or p53
proteins in Western blots, respectively.
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Mdm2-mediated SHP decrease is not affected by deletion of its
RING or acidic domain, conﬁrming that the interaction between
SHP and Mdm2 through K170 is critical for their cross-regulation.
The autoregulatory feedback loop between SHP and Mdm2 is
somewhat similar, although not identical, to the regulatory rela-
tionship between p53 and Mdm2. Accordingly, p53 activates
Mdm2 gene transcription [48] and Mdm2 in turn targets p53 pro-
tein for proteasomal degradation [34]. A recent study reported that
SHP was ubiquitinated at K122 and K123, and mutation of these
sites to arginine (R) increased SHP stability by reducing ubiquitina-
tion [47]. However, the SHPK122/123R protein was still rapidly de-
graded by Mdm2 (not shown), suggesting that K122 and K123 may
not be the essential residues for Mdm2-mediated SHP degradation
in the cellular context of the present study.
We are aware of one prior report of crosstalk among TR3
(Nur77), p53, and Mdm2 [49]. There are fundamental differences
with regard to the crosstalk between SHP or TR3 with Mdm2. SHP
induces Mdm2, but TR3 represses Mdm2. SHP interacts with both
Mdm2 and p53, yet TR3 interacts with p53 but not Mdm2. Mdm2
and p53 bind to each other with higher afﬁnity than to SHP,
whereas TR3 has a higher p53 binding afﬁnity and can sequestrate
p53 from Mdm2. It is apparent that SHP and TR3 play unique roles
in regulating Mdm2 pathway which results in distinct outcomes. It
remains to be determined whether the interaction between SHP
and TR3 [50] affects the crosstalk between SHP and Mdm2.
In summary, our results establish a critical role for SHP in keep-
ing the protein level of Mdm2 in check. SHP itself is also tightly
regulated by Mdm2 in a negative feedback fashion. Future studies
will be focused on elucidating how their cross-regulation affects
the function of Mdm2 and SHP in carcinogenesis.
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